Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.
Individual Disclosures for the NCCN Small Bowel Adenocarcinoma Panel
NooneAM, HowladerN, KrapchoM, . SEER Cancer Statistics Review, 1975-2015, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. National Cancer Institute, Bethesda, MD. 2018. Available at https://seer.cancer.gov/csr/1975_2015/. Accessed August 2, 2019.
NooneAM, HowladerN, KrapchoM, . SEER Cancer Statistics Review, 1975-2015, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. National Cancer Institute, Bethesda, MD. 2018. Available at https://seer.cancer.gov/csr/1975_2015/. Accessed August 2, 2019.)| false
BilimoriaKY, BentremDJ, WayneJD, . Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg2009;249:63–71.
BilimoriaKY, BentremDJ, WayneJD, . Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009;249:63–71.10.1097/SLA.0b013e31818e464119106677)| false
LocherC, BatumonaB, AfchainP, .Thésaurus National de Cancérologie Digestive (TNCD). Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis2018;50:15–19.
LocherC, BatumonaB, AfchainP, .Thésaurus National de Cancérologie Digestive (TNCD). Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 2018;50:15–19.2917456810.1016/j.dld.2017.09.123)| false
BennettCM, ColemanHG, VealPG, . Lifestyle factors and small intestine adenocarcinoma risk: a systematic review and meta-analysis. Cancer Epidemiol2015;39:265–273.
BennettCM, ColemanHG, VealPG, . Lifestyle factors and small intestine adenocarcinoma risk: a systematic review and meta-analysis. Cancer Epidemiol 2015;39:265–273.10.1016/j.canep.2015.02.001)| false
BoffettaP, HazeltonWD, ChenY, . Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine--a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium. Ann Oncol2012;23:1894–1898.
BoffettaP, HazeltonWD, ChenY, . Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine--a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium. Ann Oncol 2012;23:1894–1898.10.1093/annonc/mdr56222147734)| false
AlgabaA, GuerraI, Marín-JiménezI, . Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohn’s Colitis2015;9:326–333.
AlgabaA, GuerraI, Marín-JiménezI, . Incidence, management, and course of cancer in patients with inflammatory bowel disease. J Crohn’s Colitis 2015;9:326–333.10.1093/ecco-jcc/jjv032)| false
CahillC, GordonPH, PetrucciA, . Small bowel adenocarcinoma and Crohn’s disease: any further ahead than 50 years ago?World J Gastroenterol2014;20:11486–11495.
CahillC, GordonPH, PetrucciA, . Small bowel adenocarcinoma and Crohn’s disease: any further ahead than 50 years ago?World J Gastroenterol 2014;20:11486–11495.2520625610.3748/wjg.v20.i33.11486)| false
GrolleauC, PoteNM, GuedjNS, . Small bowel adenocarcinoma complicating Crohn’s disease: a single-centre experience emphasizing the importance of screening for dysplasia. Virchows Arch2017;471:611–617.
GrolleauC, PoteNM, GuedjNS, . Small bowel adenocarcinoma complicating Crohn’s disease: a single-centre experience emphasizing the importance of screening for dysplasia. Virchows Arch 2017;471:611–617.10.1007/s00428-017-2125-z28421339)| false
BenhammaneH, El M’rabetFZ, Idrissi SerhouchniK, . Small bowel adenocarcinoma complicating coeliac disease: a report of three cases and the literature review. Case Rep Oncol Med2012;2012:935183.
BenhammaneH, El M’rabetFZ, Idrissi SerhouchniK, . Small bowel adenocarcinoma complicating coeliac disease: a report of three cases and the literature review. Case Rep Oncol Med 2012;2012:935183.23243535)| false
ZulloA, De FrancescoV, MantaR, . A challenging diagnosis of jejunal adenocarcinoma in a celiac patient: case report and systematic review of the literature. J Gastrointestin Liver Dis2017;26:411–415.
ZulloA, De FrancescoV, MantaR, . A challenging diagnosis of jejunal adenocarcinoma in a celiac patient: case report and systematic review of the literature. J Gastrointestin Liver Dis 2017;26:411–415.)| false
ShenoyS. Genetic risks and familial associations of small bowel carcinoma. World J Gastrointest Oncol 2016;8:509–519.10.4251/wjgo.v8.i6.50927326320)| false
JenneDE, ReimannH, NezuJ, . Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998;18:38–43.10.1038/ng0198-38)| false
LimW, HearleN, ShahB, . Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 2003;89:308–313.10.1038/sj.bjc.660103012865922)| false
GiardielloFM, BrensingerJD, TersmetteAC, . Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447–1453.10.1053/gast.2000.2022811113065)| false
HearleN, SchumacherV, MenkoFH, . Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006;12:3209–3215.1670762210.1158/1078-0432.CCR-06-0083)| false
KoornstraJJ, KleibeukerJH, VasenHF. Small-bowel cancer in Lynch syndrome: is it time for surveillance?Lancet Oncol 2008;9:901–905.1876024610.1016/S1470-2045(08)70232-8)| false
VasenHF, WijnenJT, MenkoFH, . Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology1996;110:1020–1027.
VasenHF, WijnenJT, MenkoFH, . Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020–1027.10.1053/gast.1996.v110.pm86129888612988)| false
HendriksYM, de JongAE, MorreauH, . Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin2006;56:213–225.
HendriksYM, de JongAE, MorreauH, . Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin 2006;56:213–225.10.3322/canjclin.56.4.21316870997)| false
BeamerLC, GrantML, EspenschiedCR, . Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol2012;30:1058–1063.
BeamerLC, GrantML, EspenschiedCR, . Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 2012;30:1058–1063.10.1200/JCO.2011.38.471922355048)| false
DabajaBS, SukiD, ProB, . Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004;101:518–526.1527406410.1002/cncr.20404)| false
HalfdanarsonTR, McWilliamsRR, DonohueJH, . A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010;199:797–803.2060972410.1016/j.amjsurg.2009.05.037)| false
HoweJR, KarnellLH, MenckHR, . The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer1999;86:2693–2706.
HoweJR, KarnellLH, MenckHR, . The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer 1999;86:2693–2706.10.1002/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U10594865)| false
OvermanMJ, HuCY, KopetzS, . A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol2012;19:1439–1445.
OvermanMJ, HuCY, KopetzS, . A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol 2012;19:1439–1445.10.1245/s10434-011-2173-622187121)| false
NegoiI, PaunS, HostiucS, . Most small bowel cancers are revealed by a complication. Einstein (Sao Paulo) 2015;13:500–505.2667627110.1590/S1679-45082015AO3380)| false
GustafssonBI, SiddiqueL, ChanA, . Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. Int J Oncol2008;33:1121–1131.
GustafssonBI, SiddiqueL, ChanA, . Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. Int J Oncol 2008;33:1121–1131.)| false
HaraAK, LeightonJA, SharmaVK, . Imaging of small bowel disease: comparison of capsule endoscopy, standard endoscopy, barium examination, and CT. Radiographics2005;25:697–711., discussion 711–718.
HaraAK, LeightonJA, SharmaVK, . Imaging of small bowel disease: comparison of capsule endoscopy, standard endoscopy, barium examination, and CT. Radiographics 2005;25:697–711., discussion 711–718.10.1148/rg.25304513415888619)| false
ChenWG, ShanGD, ZhangH, . Double-balloon enteroscopy in small bowel diseases: eight years single-center experience in China. Medicine (Baltimore)2016;95:e5104.
ChenWG, ShanGD, ZhangH, . Double-balloon enteroscopy in small bowel diseases: eight years single-center experience in China. Medicine (Baltimore) 2016;95:e5104.2775963910.1097/MD.0000000000005104)| false
CazzatoIA, CammarotaG, NistaEC, . Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. Dig Liver Dis2007;39:483–487.
CazzatoIA, CammarotaG, NistaEC, . Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. Dig Liver Dis 2007;39:483–487.10.1016/j.dld.2007.01.019)| false
MitsuiK, TanakaS, YamamotoH, . Role of double-balloon endoscopy in the diagnosis of small-bowel tumors: the first Japanese multicenter study. Gastrointest Endosc2009;70:498–504.
MitsuiK, TanakaS, YamamotoH, . Role of double-balloon endoscopy in the diagnosis of small-bowel tumors: the first Japanese multicenter study. Gastrointest Endosc 2009;70:498–504.10.1016/j.gie.2008.12.242)| false
SunadaK, YamamotoH, KitaH, . Clinical outcomes of enteroscopy using the double-balloon method for strictures of the small intestine. World J Gastroenterol2005;11:1087–1089.
SunadaK, YamamotoH, KitaH, . Clinical outcomes of enteroscopy using the double-balloon method for strictures of the small intestine. World J Gastroenterol 2005;11:1087–1089.10.3748/wjg.v11.i7.108715742422)| false
CobrinGM, PittmanRH, LewisBS. Increased diagnostic yield of small bowel tumors with capsule endoscopy. Cancer 2006;107:22–27.10.1002/cncr.2197516736516)| false
BaileyAA, DebinskiHS, AppleyardMN, . Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol2006;101:2237–2243.
BaileyAA, DebinskiHS, AppleyardMN, . Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol 2006;101:2237–2243.1703218710.1111/j.1572-0241.2006.00749.x)| false
CheungDY, LeeIS, ChangDK, . Capsule endoscopy in small bowel tumors: a multicenter Korean study. J Gastroenterol Hepatol 2010;25:1079–1086.2059422210.1111/j.1440-1746.2010.06292.x)| false
SoyerP, AoutM, HoeffelC, . Helical CT-enteroclysis in the detection of small-bowel tumours: a meta-analysis. Eur Radiol 2013;23:388–399.2286526910.1007/s00330-012-2595-y)| false
CroninCG, LohanDG, BrowneAM, . Magnetic resonance enterography in the evaluation of the small bowel. Semin Roentgenol 2009;44:237–243.10.1053/j.ro.2009.05.00619715789)| false
MasselliG, Di TolaM, CascianiE, . Diagnosis of small-bowel diseases: prospective comparison of multi-detector row CT enterography with MR enterography. Radiology2016;279:420–431.
CroninCG, ScottJ, KambadakoneA, . Utility of positron emission tomography/CT in the evaluation of small bowel pathology. Br J Radiol 2012;85:1211–1221.10.1259/bjr/6453457322919004)| false
SakaeH, KanzakiH, NasuJ, . The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer2017;117:1607–1613.
SakaeH, KanzakiH, NasuJ, . The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer 2017;117:1607–1613.10.1038/bjc.2017.33828982111)| false
YoungJI, Mongoue-TchokoteS, WieghardN, . Treatment and survival of small-bowel adenocarcinoma in the United States: a comparison with colon cancer. Dis Colon Rectum2016;59:306–315.
YoungJI, Mongoue-TchokoteS, WieghardN, . Treatment and survival of small-bowel adenocarcinoma in the United States: a comparison with colon cancer. Dis Colon Rectum 2016;59:306–315.10.1097/DCR.000000000000056226953989)| false
OvermanMJ, HuCY, WolffRA, . Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer2010;116:5374–5382.
OvermanMJ, HuCY, WolffRA, . Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 2010;116:5374–5382.2071516210.1002/cncr.25324)| false
TranTB, QadanM, DuaMM, . Prognostic relevance of lymph node ratio and total lymph node count for small bowel adenocarcinoma. Surgery 2015;158:486–493.10.1016/j.surg.2015.03.04826013988)| false
WilhelmA, MüllerSA, SteffenT, . Patients with adenocarcinoma of the small intestine with 9 or more regional lymph nodes retrieved have a higher rate of positive lymph nodes and improved survival. J Gastrointest Surg2016;20:401–410.
WilhelmA, MüllerSA, SteffenT, . Patients with adenocarcinoma of the small intestine with 9 or more regional lymph nodes retrieved have a higher rate of positive lymph nodes and improved survival. J Gastrointest Surg 2016;20:401–410.2648733410.1007/s11605-015-2994-x)| false
WuS, ChenJN, ZhangQW, . A new metastatic lymph node classification-based survival predicting model in patients with small bowel adenocarcinoma: A derivation and validation study. EBioMedicine2018;32:134–141.
WuS, ChenJN, ZhangQW, . A new metastatic lymph node classification-based survival predicting model in patients with small bowel adenocarcinoma: A derivation and validation study. EBioMedicine 2018;32:134–141.10.1016/j.ebiom.2018.05.02229908920)| false
ZhangS, YuanW, ZhangJ, . Clinicopathological features, surgical treatments, and survival outcomes of patients with small bowel adenocarcinoma. Medicine (Baltimore)2017;96:e7713.
ZhangS, YuanW, ZhangJ, . Clinicopathological features, surgical treatments, and survival outcomes of patients with small bowel adenocarcinoma. Medicine (Baltimore) 2017;96:e7713.2876761010.1097/MD.0000000000007713)| false
HashimotoD, ArimaK, ChikamotoA, . Limited resection of the duodenum for nonampullary duodenal tumors, with review of the literature. Am Surg2016;82:1126–1132.
HashimotoD, ArimaK, ChikamotoA, . Limited resection of the duodenum for nonampullary duodenal tumors, with review of the literature. Am Surg 2016;82:1126–1132.28206943)| false
OnkendiEO, BoostromSY, SarrMG, . 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas. J Gastrointest Surg2012;16:682–691.
OnkendiEO, BoostromSY, SarrMG, . 15-year experience with surgical treatment of duodenal carcinoma: a comparison of periampullary and extra-ampullary duodenal carcinomas. J Gastrointest Surg 2012;16:682–691.10.1007/s11605-011-1808-z22350721)| false
CloydJM, NortonJA, VisserBC, . Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases. Ann Surg Oncol2015;22:573–580.
CloydJM, NortonJA, VisserBC, . Does the extent of resection impact survival for duodenal adenocarcinoma? Analysis of 1,611 cases. Ann Surg Oncol 2015;22:573–580.10.1245/s10434-014-4020-z25160736)| false
U.S. National Library of Medicine. Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma (BALLAD). ClinicalTrials.gov: 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02502370. Accessed January 9, 2019.
68.
EvansTRJ, AparicioT, MalicotKL, . GLOBAL BALLAD: an International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002). [abstract]J Clin Oncol2016;34(15_suppl):TPS4154–TPS4154.
EvansTRJ, AparicioT, MalicotKL, . GLOBAL BALLAD: an International Rare Cancers Initiative trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI 002). [abstract]J Clin Oncol 2016;34(15_suppl):TPS4154–TPS4154.10.1200/JCO.2016.34.15_suppl.TPS4154)| false
EckerBL, McMillanMT, DattaJ, . Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: a propensity score-matched analysis. Cancer2016;122:693–701.
EckerBL, McMillanMT, DattaJ, . Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: a propensity score-matched analysis. Cancer 2016;122:693–701.10.1002/cncr.2984026717303)| false
KelseyCR, NelsonJW, WillettCG, . Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys2007;69:1436–1441.
KelseyCR, NelsonJW, WillettCG, . Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;69:1436–1441.1768903210.1016/j.ijrobp.2007.05.006)| false
AydinD, SendurMA, KefeliU, . Evaluation of prognostic factors and adjuvant chemotherapy in patients with small bowel adenocarcinoma who underwent curative resection. Clin Colorectal Cancer2017;16:220–227.
AydinD, SendurMA, KefeliU, . Evaluation of prognostic factors and adjuvant chemotherapy in patients with small bowel adenocarcinoma who underwent curative resection. Clin Colorectal Cancer 2017;16:220–227.2767089310.1016/j.clcc.2016.08.002)| false
YeX, ZhangG, ChenH, . Meta-analysis of postoperative adjuvant therapy for small bowel adenocarcinoma. PLoS One 2018;13:e0200204.3009615010.1371/journal.pone.0200204)| false
KimK, ChieEK, JangJY, . Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience. Am J Clin Oncol 2012;35:533–536.10.1097/COC.0b013e31821dee3121659832)| false
OvermanMJ, KopetzS, LinE, . Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine?Acta Oncol 2010;49:474–479.10.3109/02841860903490051)| false
EckerBL, McMillanMT, DattaJ, . Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: a propensity score-matched analysis of a nationwide clinical oncology database. Cancer2017;123:967–976.
EckerBL, McMillanMT, DattaJ, . Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: a propensity score-matched analysis of a nationwide clinical oncology database. Cancer 2017;123:967–976.10.1002/cncr.3043928263387)| false
MarkowitzSD, BertagnolliMM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449–2460.10.1056/NEJMra080458820018966)| false
KimGP, ColangeloLH, WieandHS, . Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol2007;25:767–772.
KimGP, ColangeloLH, WieandHS, . Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007;25:767–772.10.1200/JCO.2006.05.817217228023)| false
KlingbielD, SaridakiZ, RothAD, . Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol2015;26:126–132.
KlingbielD, SaridakiZ, RothAD, . Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol 2015;26:126–132.2536198210.1093/annonc/mdu499)| false
RibicCM, SargentDJ, MooreMJ, . Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med2003;349:247–257.
RibicCM, SargentDJ, MooreMJ, . Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247–257.10.1056/NEJMoa02228912867608)| false
SargentDJ, MarsoniS, MongesG, . Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol2010;28:3219–3226.
SargentDJ, MarsoniS, MongesG, . Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219–3226.2049839310.1200/JCO.2009.27.1825)| false
KimJE, HongYS, KimHJ, . Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy. Ann Surg Oncol2015; 22(S3, Suppl 3)S630–S637.
KimJE, HongYS, KimHJ, . Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy. Ann Surg Oncol 2015; 22(S3, Suppl 3)S630–S637.10.1245/s10434-015-4807-6)| false
HutchinsG, SouthwardK, HandleyK, . Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol2011;29:1261–1270.
HutchinsG, SouthwardK, HandleyK, . Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29:1261–1270.10.1200/JCO.2010.30.136621383284)| false
BertagnolliMM, RedstonM, ComptonCC, . Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol2011;29:3153–3162.
BertagnolliMM, RedstonM, ComptonCC, . Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 2011;29:3153–3162.10.1200/JCO.2010.33.009221747089)| false
ComptonCC, FieldingLP, BurgartLJ, . Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med2000;124:979–994.
ComptonCC, FieldingLP, BurgartLJ, . Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979–994.)| false
FujitaS, ShimodaT, YoshimuraK, . Prospective evaluation of prognostic factors in patients with colorectal cancer undergoing curative resection. J Surg Oncol2003;84:127–131.
LiebigC, AyalaG, WilksJ, . Perineural invasion is an independent predictor of outcome in colorectal cancer. J Clin Oncol 2009;27:5131–5137.1973811910.1200/JCO.2009.22.4949)| false
GrotheyA, SobreroAF, ShieldsAF, . Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378:1177–1188.10.1056/NEJMoa171370929590544)| false
YeungRS, WeeseJL, HoffmanJP, . Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer 1993;72:2124–2133.837487110.1002/1097-0142(19931001)72:7<2124::AID-CNCR2820720711>3.0.CO;2-C)| false
CoiaL, HoffmanJ, ScherR, . Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994;30:161–167.10.1016/0360-3016(94)90531-28083109)| false
CiresiDL, ScholtenDJ. The continuing clinical dilemma of primary tumors of the small intestine. Am Surg 1995;61:698–702., discussion 702–703.7618809)| false
OhSY, EdwardsA, MandelsonM, . Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancreatic cancer. Gastrointest Endosc2015;82:460–8.e2.
OhSY, EdwardsA, MandelsonM, . Survival and clinical outcome after endoscopic duodenal stent placement for malignant gastric outlet obstruction: comparison of pancreatic cancer and nonpancreatic cancer. Gastrointest Endosc 2015;82:460–8.e2.2585116210.1016/j.gie.2015.01.026)| false
van den BergMW, HaijtinkS, FockensP, . First data on the Evolution duodenal stent for palliation of malignant gastric outlet obstruction (DUOLUTION study): a prospective multicenter study. Endoscopy2013;45:174–181.
van den BergMW, HaijtinkS, FockensP, . First data on the Evolution duodenal stent for palliation of malignant gastric outlet obstruction (DUOLUTION study): a prospective multicenter study. Endoscopy 2013;45:174–181.10.1055/s-0032-1326077)| false
AdamR, ChicheL, AloiaT, .; Association Française de Chirurgie. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg2006;244:524–535.
AdamR, ChicheL, AloiaT, .; Association Française de Chirurgie. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006;244:524–535.16998361)| false
RompteauxP, GagnièreJ, GornetJM, . Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study. Eur J Surg Oncol2019;45:331–335.
RoversKP, de BreeE, YonemuraY, . Treatment of peritoneal metastases from small bowel adenocarcinoma. Int J Hyperthermia 2017;33:571–578.2791918110.1080/02656736.2016.1266700)| false
LeguéLM, SimkensGA, CreemersGM, . Synchronous peritoneal metastases of small bowel adenocarcinoma: Insights into an underexposed clinical phenomenon. Eur J Cancer2017;87:84–91.
LeguéLM, SimkensGA, CreemersGM, . Synchronous peritoneal metastases of small bowel adenocarcinoma: Insights into an underexposed clinical phenomenon. Eur J Cancer 2017;87:84–91.2913206110.1016/j.ejca.2017.10.012)| false
EliasD, GlehenO, PocardM, . A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg2010;251:896–901.
EliasD, GlehenO, PocardM, . A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg 2010;251:896–901.2039584310.1097/SLA.0b013e3181d9765d)| false
LiuY, IshibashiH, TakeshitaK, . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from small bowel malignancy: results from a single specialized center. Ann Surg Oncol2016;23:1625–1631.
LiuY, IshibashiH, TakeshitaK, . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from small bowel malignancy: results from a single specialized center. Ann Surg Oncol 2016;23:1625–1631.10.1245/s10434-015-5056-426717938)| false
LiuY, YonemuraY, LevineEA, . Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastases from a small bowel adenocarcinoma: multi-institutional experience. Ann Surg Oncol2018;25:1184–1192.
LiuY, YonemuraY, LevineEA, . Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastases from a small bowel adenocarcinoma: multi-institutional experience. Ann Surg Oncol 2018;25:1184–1192.2948456510.1245/s10434-018-6369-x)| false
SaxenaA, ValleSJ, LiauwW, . Recurrence and survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for small bowel adenocarcinoma. Anticancer Res2017;37:5737–5742.
SaxenaA, ValleSJ, LiauwW, . Recurrence and survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for small bowel adenocarcinoma. Anticancer Res 2017;37:5737–5742.28982894)| false
van OudheusdenTR, LemmensVE, BraamHJ, . Peritoneal metastases from small bowel cancer: results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. Surgery2015;157:1023–1027.
van OudheusdenTR, LemmensVE, BraamHJ, . Peritoneal metastases from small bowel cancer: results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. Surgery 2015;157:1023–1027.10.1016/j.surg.2015.01.021)| false
CzaykowskiP, HuiD. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol)2007;19:143–149.
CzaykowskiP, HuiD. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol) 2007;19:143–149.10.1016/j.clon.2006.12.00117355111)| false
JigyasuD, BedikianAY, StroehleinJR. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 1984;53:23–25.669000110.1002/1097-0142(19840101)53:1<23::AID-CNCR2820530106>3.0.CO;2-U)| false
ZhangL, WangLY, DengYM, . Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China. J BUON2011;16:689–696.
ZhangL, WangLY, DengYM, . Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China. J BUON 2011;16:689–696.22331723)| false
AydinD, SendurMA, KefeliU, . Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO). J BUON2016;21:1242–1249.
AydinD, SendurMA, KefeliU, . Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO). J BUON 2016;21:1242–1249.27837629)| false
ThotaR, GonzalezRS, BerlinJ, . Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma?Am J Clin Pathol2017;148:208–214.
ThotaR, GonzalezRS, BerlinJ, . Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma?Am J Clin Pathol 2017;148:208–214.10.1093/AJCP/AQX07028821192)| false
LaforestA, AparicioT, ZaananA, . ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Eur J Cancer 2014;50:1740–1746.10.1016/j.ejca.2014.04.00724797764)| false
TakayoshiK, KusabaH, UenomachiM, . Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol2017;80:333–342.
TakayoshiK, KusabaH, UenomachiM, . Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol 2017;80:333–342.10.1007/s00280-017-3371-028653251)| false
GulhatiP, RaghavK, ShroffR, . Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater. Oncologist2018;23:277–e26.
GulhatiP, RaghavK, ShroffR, . Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater. Oncologist 2018;23:277–e26.10.1634/theoncologist.2017-0568)| false
OvermanMJ, VaradhacharyGR, KopetzS, . Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol2009;27:2598–2603.
OvermanMJ, VaradhacharyGR, KopetzS, . Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009;27:2598–2603.1916420310.1200/JCO.2008.19.7145)| false
XiangXJ, LiuYW, ZhangL, . A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs2012;23:561–566.
XiangXJ, LiuYW, ZhangL, . A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anticancer Drugs 2012;23:561–566.10.1097/CAD.0b013e328350dd0d22481063)| false
HorimatsuT, NakayamaN, MoriwakiT, . A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. Int J Clin Oncol2017;22:905–912.
HorimatsuT, NakayamaN, MoriwakiT, . A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. Int J Clin Oncol 2017;22:905–912.2853682610.1007/s10147-017-1138-6)| false
GibsonMK, HolcroftCA, KvolsLK, . Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist2005;10:132–137.
GibsonMK, HolcroftCA, KvolsLK, . Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005;10:132–137.10.1634/theoncologist.10-2-13215709215)| false
TsushimaT, TaguriM, HonmaY, . Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist2012;17:1163–1170.
TsushimaT, TaguriM, HonmaY, . Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist 2012;17:1163–1170.2262214910.1634/theoncologist.2012-0079)| false
McWilliamsRR, FosterNR, MahoneyMR, . North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer2017;123:3494–3501.
McWilliamsRR, FosterNR, MahoneyMR, . North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 2017;123:3494–3501.2849330810.1002/cncr.30766)| false
GulhatiP, RaghavK, ShroffRT, . Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater: a single-center, open-label, phase 2 study. Cancer2017;123:1011–1017.
GulhatiP, RaghavK, ShroffRT, . Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of Vater: a single-center, open-label, phase 2 study. Cancer 2017;123:1011–1017.2785901010.1002/cncr.30445)| false
AydinD, SendurMA, KefeliU, . Evaluation of bevacizumab in advanced small bowel adenocarcinoma. Clin Colorectal Cancer 2017;16:78–83.2724708910.1016/j.clcc.2016.04.013)| false
PedersenK, FosterN, OvermanM, . ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA) [abstract]. Ann Oncol2019;30(Suppl): Abstract # O-007.
PedersenK, FosterN, OvermanM, . ZEBRA: an ACCRU/IRCI multicenter phase 2 study of pembrolizumab in patients with advanced small bowel adenocarcinoma (SBA) [abstract]. Ann Oncol 2019;30(Suppl): Abstract # O-007.)| false
OvermanMJ, McDermottR, LeachJL, . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol2017;18:1182–1191.
OvermanMJ, McDermottR, LeachJL, . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182–1191.10.1016/S1470-2045(17)30422-928734759)| false
OvermanMJ, AdamL, RaghavK, . Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol2018;29:139–144.
OvermanMJ, AdamL, RaghavK, . Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 2018;29:139–144.2906927910.1093/annonc/mdx688)| false
ZaananA, GauthierM, MalkaD, . Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer2011;117:1422–1428.
ZaananA, GauthierM, MalkaD, . Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 2011;117:1422–1428.2142514210.1002/cncr.25614)| false
DrilonA, LaetschTW, KummarS, . Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731–739.10.1056/NEJMoa171444829466156)| false
U.S. Food and Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions. 2018. Available at: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm626720.htm. Accessed November 30, 2018.)| false
KimM, JangHJ. The role of small bowel endoscopy in small bowel Crohn’s disease: when and how?Intest Res 2016;14:211–217.2743314210.5217/ir.2016.14.3.211)| false
SimonM, CosnesJ, GornetJM, .GETAID group. Endoscopic detection of small bowel dysplasia and adenocarcinoma in Crohn’s disease: A prospective cohort-study in high-risk patients. J Crohn’s Colitis2017;11:47–52.
SimonM, CosnesJ, GornetJM, .GETAID group. Endoscopic detection of small bowel dysplasia and adenocarcinoma in Crohn’s disease: A prospective cohort-study in high-risk patients. J Crohn’s Colitis 2017;11:47–52.10.1093/ecco-jcc/jjw123)| false
HaanstraJF, Al-TomaA, DekkerE, . Prevalence of small-bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy. Gut 2015;64:1578–1583.2520965710.1136/gutjnl-2014-307348)| false
KoornstraJJ. Small bowel endoscopy in familial adenomatous polyposis and Lynch syndrome. Best Pract Res Clin Gastroenterol 2012;26:359–368.2270457710.1016/j.bpg.2012.01.022)| false
PostgateA, HyerW, PhillipsR, . Feasibility of video capsule endoscopy in the management of children with Peutz-Jeghers syndrome: a blinded comparison with barium enterography for the detection of small bowel polyps. J Pediatr Gastroenterol Nutr2009;49:417–423.
PostgateA, HyerW, PhillipsR, . Feasibility of video capsule endoscopy in the management of children with Peutz-Jeghers syndrome: a blinded comparison with barium enterography for the detection of small bowel polyps. J Pediatr Gastroenterol Nutr 2009;49:417–423.10.1097/MPG.0b013e31818f0a1f19543117)| false
SerranoM, Mão-de-FerroS, PinhoR, . Double-balloon enteroscopy in the management of patients with Peutz-Jeghers syndrome: a retrospective cohort multicenter study. Rev Esp Enferm Dig2013;105:594–599.
SerranoM, Mão-de-FerroS, PinhoR, . Double-balloon enteroscopy in the management of patients with Peutz-Jeghers syndrome: a retrospective cohort multicenter study. Rev Esp Enferm Dig 2013;105:594–599.2464145610.4321/S1130-01082013001000004)| false
van LierMG, WagnerA, Mathus-VliegenEM, . High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol2010;105:1258–1264., author reply 1265.
van LierMG, WagnerA, Mathus-VliegenEM, . High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010;105:1258–1264., author reply 1265.10.1038/ajg.2009.725)| false
DriniM, SpeerA, DowC, . Management of duodenal adenomatosis in FAP: single centre experience. Fam Cancer 2012;11:167–173.10.1007/s10689-011-9496-022131053)| false
HewittM, GreenfieldS, and StovallE, (eds). From Cancer Patient to Cancer Survivor: Lost in Transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council. Washington, DC: National Academy of Sciences;2006. Available at http://www.nap.edu/catalog/11468.html
HewittM, GreenfieldS, and StovallE, (eds). From Cancer Patient to Cancer Survivor: Lost in Transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council. Washington, DC: National Academy of Sciences;2006. Available at http://www.nap.edu/catalog/11468.html)| false
JansenL, HerrmannA, StegmaierC, . Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study. J Clin Oncol2011;29:3263–3269.
JansenL, HerrmannA, StegmaierC, . Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study. J Clin Oncol 2011;29:3263–3269.10.1200/JCO.2010.31.401321768465)| false
LynchBM, StegingaSK, HawkesAL, . Describing and predicting psychological distress after colorectal cancer. Cancer 2008;112:1363–1370.1831804410.1002/cncr.23300)| false
MolsF, BeijersT, LemmensV, . Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol2013;31:2699–2707.
MolsF, BeijersT, LemmensV, . Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013;31:2699–2707.2377595110.1200/JCO.2013.49.1514)| false
ThongMS, MolsF, WangXS, . Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. Eur J Cancer2013;49:1957–1966.
ThongMS, MolsF, WangXS, . Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. Eur J Cancer 2013;49:1957–1966.2345375010.1016/j.ejca.2013.01.012)| false
WrightP, DowningA, MorrisEJ, . Identifying social distress: a cross-sectional survey of social outcomes 12 to 36 months after colorectal cancer diagnosis. J Clin Oncol2015;33:3423–3430.
WrightP, DowningA, MorrisEJ, . Identifying social distress: a cross-sectional survey of social outcomes 12 to 36 months after colorectal cancer diagnosis. J Clin Oncol 2015;33:3423–3430.2628263610.1200/JCO.2014.60.6129)| false
DenlingerCS, BarsevickAM. The challenges of colorectal cancer survivorship. J Natl Compr Canc Netw 2009;7:883–894.10.6004/jnccn.2009.005819755048)| false
